Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Allergy to soy is common, and the food is listed with other foods that commonly cause allergy, such as milk, eggs, peanuts, tree nuts, and shellfish. The problem has been reported among younger children, and the diagnosis of soy allergy is often based on symptoms reported by parents and results of skin tests or blood tests for allergy. Only a few reported studies have attempted to confirm allergy to soy by direct challenge with the food under controlled conditions. It is very difficult to give a reliable estimate of the true prevalence of soy allergy in the general population. To the extent that it does exist, soy allergy may cause cases of urticaria and angioedema, usually within minutes to hours of ingestion. In rare cases, true anaphylaxis may also occur. The reason for the discrepancy is likely that soy proteins, the causative factor in allergy, are far less potent at triggering allergy symptoms than the proteins of peanut and shellfish. An allergy test that is positive demonstrates that the immune system has formed IgE antibodies to soy proteins. However, this is only a factor when soy proteins reach the blood without being digested, in sufficient quantities to reach a threshold to provoke actual symptoms. Soy can also trigger symptoms via food intolerance, a situation where no allergic mechanism can be proven. One scenario is seen in very young infants who have vomiting and diarrhoea when fed soy-based formula, which resolves when the formula is withdrawn.
alkane Also paraffin. Any fully saturated acyclic hydrocarbon,An acyclic saturated hydrocarbon containing only carbon and hydrogen atoms with only single carbon–carbon bonds; alkanes generally have the formula CnH2n+2. i.e. one in which all carbon–carbon bonds are single bonds.
=== Film and television === AAA, la película: sin límite en el tiempo, a 2010 Mexican movie Anbanavan Asaradhavan Adangadhavan, a 2017 Indian Tamil-language movie Associated Argentine Artists (Spanish: Artistas Argentinos Asociados), an Argentine movie distribution company Spearhead from Space, a 1970 Doctor Who serial (production code "AAA")
Sources: en.wikipedia.org
The proteins in black mamba venom are of low molecular weight, low viscosity, and the venom's high activity in terms of hyaluronidases, which is also essential in facilitating dispersion of venom toxins throughout tissue (spreading the venom through the body) by catalyzing the hydrolysis of hyaluronan, a constituent of the extracellular matrix (ECM), hyaluronidase lowers the viscosity of hyaluronan, and Dendroaspin natriuretic peptide (DNP), a newly discovered component of mamba venom, is the most potent natriuretic peptide and is unique to the genus Dendroaspis, or mambas. It is a polypeptide analogous to the human atrial natriuretic peptide; it is responsible for causing diuresis through natriuresis and dilating the vessel bloodstream, which results in, among other effects, acceleration of venom distribution in the body of the victim, thereby increasing tissue permeability. These advanced and highly evolved physical and biological features combined with this species' large size, explosive aggression, and quickness make the black mamba a terrifying adversary. Neurological, respiratory, and cardiovascular symptoms rapidly begin to manifest, usually within less than ten minutes. Common symptoms are rapid onset of dizziness, drowsiness, headache, coughing or difficulty breathing, convulsions, and an erratic heartbeat.
Garden officials called the plans "pie-in-the-sky", but on July 24, 2013, the New York City Council voted 47–1 to give the Garden a ten-year operating permit, after which the owners would have to move or seek permission anew. In January 2016, at the same time he announced the development of Moynihan Train Hall, New York governor Andrew Cuomo announced he would solicit proposals for the redevelopment of the station under the Garden as a public-private partnership called the Empire Station Complex. In June 2023, nearing the end of the ten-year permit granted in 2013, the MTA, Amtrak, and NJ Transit filed a report stating Madison Square Garden was no longer compatible with Penn Station, saying, "MSG's existing configuration and property boundaries impose severe constraints." On September 14, 2023, the New York City Council voted 48–0 to renew the operating permit for Madison Square Garden for five years, the shortest-ever granted to the Garden by the city.
Monosynaptic reflex A reflex arc that involves only one synapse between a sensory neuron and a motor neuron, such as the knee-jerk (patellar) reflex. Mossy fiber A type of excitatory input fiber to the cerebellum originating from the spinal cord and brainstem nuclei. They synapse onto granule cells. Motor cortex A region of the frontal lobe involved in planning, controlling, and executing voluntary movements. Motor neuron A type of neuron that transmits signals from the central nervous system to muscles or glands, enabling movement and action. Motor unit A motor neuron and all the muscle fibers it innervates. Varies in size depending on the precision required by the muscle. MRI spectroscopy A specialized MRI technique that measures concentrations of certain brain chemicals or metabolites, aiding in diagnosis of tumors and metabolic disorders. Multisensory integration The process by which the brain combines information from different sensory modalities (e.g., vision and sound) to create coherent perception. Myelin A fatty substance that insulates axons, increasing the speed and efficiency of action potential conduction. Formed by oligodendrocytes in the CNS and Schwann cells in the PNS. Myelination The process of forming a myelin sheath around axons, critical for normal neural function. Occurs progressively during development. Myoclonus Sudden, involuntary muscle jerks or twitches. Can be physiological (e.g., sleep starts) or associated with neurological disorders.
UIP pattern: Honeycombing, with or without peripheral traction bronchiectasis; or bronchiolectasis (dilatation of the terminal bronchioles) Predominantly subpleural and basal Often heterogenous distribution, being occasionally diffuse, and may be asymmetrical There may be superimposed CT features such as mild ground-glass opacity, reticular pattern and pulmonary ossification.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.